KEW Group Inc., a Cambridge, MA-based oncology services company, completed a $16.8m Series B financing.
The round was led by Signet Healthcare Partners with participation from new investors Amzak Capital Management and Arsenal Capital Management and existing backer The Boylston Street Group.
The company intends to use the funds to commercialize CancerPlexSM and KEW Therapeutic Pathways, expand partnership activities with Cardinal Health, and deploy the KEW Oncology Network.
Led by Scott Schell, Ph.D., M.D., MBA, president and CEO, KEW provides oncologists with practical, action-oriented solutions which couple patient-specific, genomic data with clinical intelligence about approved and emerging therapies. CancerPlex is a genetic/genomic test for molecular diagnosis of solid tumors. TPx Treatment Pathways allows oncologists to utilize advancements in drug development and genomic science to select individualized, patient-specific treatment approaches.